Skip to Content

Biktarvy Dosage

Generic name: BICTEGRAVIR SODIUM 50mg, EMTRICITABINE 200mg, TENOFOVIR ALAFENAMIDE FUMARATE 25mg
Dosage form: tablet

Medically reviewed by Drugs.com. Last updated on Sep 17, 2018.

Testing When Initiating and During Treatment with BIKTARVY

Prior to or when initiating BIKTARVY, test patients for hepatitis B virus infection [see Warnings and Precautions (5.1)] .

Prior to or when initiating BIKTARVY, and during treatment with BIKTARVY, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings and Precautions (5.4)].

Recommended Dosage

BIKTARVY is a three-drug fixed dose combination product containing 50 mg of bictegravir (BIC), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of BIKTARVY is one tablet taken orally once daily with or without food [see Clinical Pharmacology (12.3)] .

Not Recommended in Patients with Severe Renal Impairment

BIKTARVY is not recommended in patients with estimated creatinine clearance below 30 mL per minute [see Use in Specific Populations (8.6)] .

Not Recommended in Patients with Severe Hepatic Impairment

BIKTARVY is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions

More about Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)

Consumer resources

Professional resources

Related treatment guides

Hide